OncoMatch/Clinical Trials/NCT06177301
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Is NCT06177301 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Tislelizumab combined with GX and Tislelizumab combined with GP for nasopharyngeal carcinoma.
Treatment: Tislelizumab combined with GX · Tislelizumab combined with GP — The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: PD-1 monoclonal antibody
Patients who had previously received PD-1 monoclonal antibody
Cannot have received: PD-L1 monoclonal antibody
Patients who had previously received ... PD-L1 monoclonal antibody
Cannot have received: CTLA4 monoclonal antibody
Patients who had previously received ... CTLA4 monoclonal antibody
Lab requirements
Blood counts
Hemoglobin (HB) ≥ 90g / L; Neutrophil count (ANC) ≥ 1.5 × 10^9 / L; platelets (PLT) ≥ 80 × 10^9 / L
Kidney function
Albumin ≥ 28g / L; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60 ml / min
Liver function
Serum total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 × ULN; if liver metastasis, ALT and AST ≤ 5 × ULN
Blood routine examination: 1) Hemoglobin (HB)≥ 90g / L; 2) Neutrophil count (ANC) ≥ 1.5 × 10^9 / L; 3) platelets (PLT) ≥ 80 × 10^9 / L; Liver function: 1) Serum total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); 2) alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 × ULN; if liver metastasis, ALT and AST ≤ 5 × ULN; Renal function: Albumin ≥ 28g / L; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60 ml / min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06177301 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages